Stock Traders Buy Large Volume of Terns Pharmaceuticals Call Options (NASDAQ:TERN)

Terns Pharmaceuticals, Inc. (NASDAQ:TERN) was the recipient of some unusual options trading on Friday. Stock traders bought 9,767 call options on the stock. This represents an increase of 501% compared to the average daily volume of 1,624 call options.

Terns Pharmaceuticals Price Performance

NASDAQ TERN opened at $46.52 on Friday. Terns Pharmaceuticals has a 1-year low of $1.87 and a 1-year high of $48.26. The firm has a market capitalization of $4.83 billion, a P/E ratio of -45.17 and a beta of -0.31. The business’s 50-day simple moving average is $38.76 and its 200-day simple moving average is $26.11.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the stock. HC Wainwright raised their target price on shares of Terns Pharmaceuticals from $20.00 to $60.00 and gave the stock a “buy” rating in a research report on Tuesday, December 9th. Citizens Jmp upped their price target on shares of Terns Pharmaceuticals from $35.00 to $57.00 and gave the stock a “market outperform” rating in a research report on Thursday, December 11th. UBS Group raised shares of Terns Pharmaceuticals to a “strong-buy” rating in a research note on Thursday, December 4th. Oppenheimer lifted their price target on shares of Terns Pharmaceuticals from $28.00 to $58.00 and gave the company an “outperform” rating in a report on Tuesday, December 9th. Finally, TD Cowen raised shares of Terns Pharmaceuticals to a “strong-buy” rating in a research note on Friday, February 20th. Two research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Terns Pharmaceuticals has an average rating of “Buy” and a consensus price target of $58.11.

Insider Buying and Selling at Terns Pharmaceuticals

In other Terns Pharmaceuticals news, insider Emil Kuriakose sold 1,155 shares of the firm’s stock in a transaction dated Friday, January 2nd. The stock was sold at an average price of $38.57, for a total value of $44,548.35. Following the sale, the insider directly owned 50,365 shares of the company’s stock, valued at approximately $1,942,578.05. This trade represents a 2.24% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Amy L. Burroughs sold 71,339 shares of Terns Pharmaceuticals stock in a transaction dated Monday, January 5th. The shares were sold at an average price of $38.10, for a total value of $2,718,015.90. Following the completion of the sale, the chief executive officer owned 138,976 shares of the company’s stock, valued at $5,294,985.60. This trade represents a 33.92% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 155,826 shares of company stock valued at $5,882,597 over the last quarter. Insiders own 1.50% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Cubist Systematic Strategies LLC grew its stake in Terns Pharmaceuticals by 136.8% during the first quarter. Cubist Systematic Strategies LLC now owns 28,327 shares of the company’s stock worth $78,000 after buying an additional 16,363 shares during the period. Dynamic Technology Lab Private Ltd purchased a new position in shares of Terns Pharmaceuticals in the 1st quarter valued at $51,000. Goldman Sachs Group Inc. lifted its holdings in shares of Terns Pharmaceuticals by 21.0% during the 1st quarter. Goldman Sachs Group Inc. now owns 415,021 shares of the company’s stock valued at $1,145,000 after acquiring an additional 71,971 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of Terns Pharmaceuticals by 3.8% during the 2nd quarter. Geode Capital Management LLC now owns 1,633,349 shares of the company’s stock valued at $6,094,000 after acquiring an additional 59,145 shares in the last quarter. Finally, Candriam S.C.A. boosted its position in Terns Pharmaceuticals by 9.9% during the 2nd quarter. Candriam S.C.A. now owns 2,368,235 shares of the company’s stock worth $8,834,000 after purchasing an additional 214,266 shares during the period. 98.26% of the stock is owned by institutional investors and hedge funds.

About Terns Pharmaceuticals

Terns Pharmaceuticals, Inc is a clinical?stage biopharmaceutical company focused on developing oral small?molecule therapies for the treatment of chronic liver diseases and other serious conditions. The company’s research and development efforts center on novel mechanisms of action designed to address the underlying causes of progressive liver disorders, including inflammation, fibrosis and metabolic dysregulation. By advancing targeted compounds that can be administered orally, Terns aims to offer patients more convenient and effective treatment options compared to injectable or biologic therapies.

The company’s pipeline features several candidates in various stages of preclinical and clinical evaluation.